Protocol Ledger

NCT05420324 · Phase II · COMPLETED

A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma

Interventional Phase II clinical trial protocol NCT05420324 sponsored by Eucure (Beijing) Biopharma Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-13 Enrollment: 20 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05420324
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)20 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05420324
Protocol FieldVerified Registry Value
NCT IdentifierNCT05420324
Consolidated Lead SponsorEucure (Beijing) Biopharma Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment20 participants (ACTUAL)
Registered Start Date2022-06-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI